Show simple item record

dc.contributor.authorParker, Catriona
dc.contributor.authorWaters, R
dc.contributor.authorLeighton, Carly
dc.contributor.authorHancock, J
dc.contributor.authorSutton, R
dc.contributor.authorMoorman, A
dc.contributor.authorAncliff, P
dc.contributor.authorMorgan, M
dc.contributor.authorMasurekar, Ashish
dc.contributor.authorGoulden, N
dc.contributor.authorGreen, N
dc.contributor.authorRévész, T
dc.contributor.authorDarbyshire, P
dc.contributor.authorLove, S
dc.contributor.authorSaha, Vaskar
dc.date.accessioned2011-01-24T13:14:52Z
dc.date.available2011-01-24T13:14:52Z
dc.date.issued2010-12-11
dc.identifier.citationEffect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. 2010, 376 (9757):2009-17 Lanceten
dc.identifier.issn1474-547X
dc.identifier.pmid21131038
dc.identifier.doi10.1016/S0140-6736(10)62002-8
dc.identifier.urihttp://hdl.handle.net/10541/120280
dc.description.abstractAlthough survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens.
dc.language.isoenen
dc.subjectAnticancerous Antibioticsen
dc.subjectAnticancerous Combined Chemotherapy Protocolsen
dc.subjectPrecursor Cell Lymphoblastic Leukaemia-Lymphomaen
dc.subject.mesh6-Mercaptopurine
dc.subject.meshAdolescent
dc.subject.meshAntibiotics, Antineoplastic
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshAsparaginase
dc.subject.meshChild
dc.subject.meshChild, Preschool
dc.subject.meshCyclophosphamide
dc.subject.meshCytarabine
dc.subject.meshDexamethasone
dc.subject.meshDisease-Free Survival
dc.subject.meshEtoposide
dc.subject.meshFemale
dc.subject.meshGreat Britain
dc.subject.meshHumans
dc.subject.meshIdarubicin
dc.subject.meshInfant
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshLeukocyte Count
dc.subject.meshMale
dc.subject.meshMethotrexate
dc.subject.meshMitoxantrone
dc.subject.meshPolyethylene Glycols
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.meshRecurrence
dc.subject.meshRisk Assessment
dc.subject.meshTreatment Outcome
dc.subject.meshVidarabine
dc.subject.meshVincristine
dc.titleEffect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Children's Cancer Group, School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Science Centre, Central Manchester University Hospitals Foundation Trust, Manchester, UK.en
dc.identifier.journalLanceten
html.description.abstractAlthough survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens.


Files in this item

This item appears in the following Collection(s)

Show simple item record